Patents by Inventor Annarosa Arcangeli

Annarosa Arcangeli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mono and bispecific antibody binding to hERG1 and hERG1/integrin beta 1
    Patent number: 11572406
    Abstract: The present invention describes a bispecfic antibody composed of the variable domains (VH and VL) of two antibodies, hERG1 mAb (which binds the extracellular domain S5-P of hERG1) and of ?1 integrin mAb TS2/16 or BV7, which bind the extracellular domain of ?1 integrin. The present invention relates also to a novel anti-hERG1 molecule bearing a Cys in position 95 of the VH domain. The invention describes also their application for diagnostic and therapeutic purposes in oncology and other fields of medical sciences.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: February 7, 2023
    Assignee: UNIVERSITÀ DEGLI STUDI DI FIRENZE
    Inventors: Annarosa Arcangeli, Claudia Duranti, Laura Carraresi, Silvia Crescioli
  • MONO AND BISPECIFIC ANTIBODY BINDING TO HERG1 AND HERG1/INTEGRIN BETA 1
    Publication number: 20210147574
    Abstract: The present invention describes a bispecfic antibody composed of the variable domains (VH and VL) of two antibodies, hERG1 mAb (which binds the extracellular domain S5-P of hERG1) and of ?1 integrin mAb TS2/16 or BV7, which bind the extracellular domain of ?1 integrin. The present invention relates also to a novel anti-hERG1 molecule bearing a Cys in position 95 of the VH domain. The invention describes also their application for diagnostic and therapeutic purposes in oncology and other fields of medical sciences.
    Type: Application
    Filed: June 29, 2018
    Publication date: May 20, 2021
    Inventors: Annarosa ARCANGELI, Claudia DURANTI, Laura CARRARESI, Silvia CRESCIOLI
  • HERG1 AND GLUT-1 IN COLORECTAL CANCER
    Publication number: 20140255950
    Abstract: The present invention describes the determination of the prognostic impact of hERG1 potassium channels along with other hypoxia-related biomolecular parameters, in patients who underwent radical surgery with curative intent for non metastatic CRC.
    Type: Application
    Filed: August 10, 2012
    Publication date: September 11, 2014
    Applicant: Universita' Degli Studi Di Firenze
    Inventors: Annarosa Arcangeli, Olivia Crociani, Elena Lastraioli, Raffaella Romoli, Luca Boni, Francesco Di Costanzo
  • COMPOSITIONS FOR TREATMENT OF CHEMORESISTANT AND/OR POTENTIALLY CHEMORESISTANT LEUKAEMIAS
    Publication number: 20120309704
    Abstract: This description applies to pharmaceutical compositions comprising a mixture comprising one or more hERG1 channel blockers in combination with one or more compounds for anticancer therapy for use in the treatment of chemoresistant or potentially chemoresistant leukaemias and in vitro systems for the screening of substances suitable for use in the treatment of chemoresistant or potentially chemoresistant leukaemias.
    Type: Application
    Filed: November 10, 2010
    Publication date: December 6, 2012
    Inventors: Annarosa Arcangeli, Andrea Becchetti, Serena Pillozzi, Marika Masselli, Emanuele De Lorenzo